Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, JE[Jang, J. E.] | - |
dc.contributor.author | Min, YH[Min, Y. H.] | - |
dc.contributor.author | Yoon, J[Yoon, J.] | - |
dc.contributor.author | Kim, I[Kim, I.] | - |
dc.contributor.author | Lee, JH[Lee, J-H] | - |
dc.contributor.author | Jung, CW[Jung, C. W.] | - |
dc.contributor.author | Shin, HJ[Shin, H-J] | - |
dc.contributor.author | Lee, WS[Lee, W. S.] | - |
dc.contributor.author | Lee, JH[Lee, J. H.] | - |
dc.contributor.author | Hong, DS[Hong, D-S] | - |
dc.contributor.author | Kim, HJ[Kim, H-J] | - |
dc.contributor.author | Kim, HJ[Kim, H-J] | - |
dc.contributor.author | Park, S[Park, S.] | - |
dc.contributor.author | Lee, KH[Lee, K-H] | - |
dc.contributor.author | Jang, JH[Jang, J. H.] | - |
dc.contributor.author | Chung, JS[Chung, J. S.] | - |
dc.contributor.author | Lee, SM[Lee, S. M.] | - |
dc.contributor.author | Park, J[Park, J.] | - |
dc.contributor.author | Park, SK[Park, S. K.] | - |
dc.contributor.author | Ahn, JS[Ahn, J-S] | - |
dc.contributor.author | Min, WS[Min, W-S] | - |
dc.contributor.author | Cheong, JW[Cheong, J-W] | - |
dc.date.accessioned | 2021-08-02T05:35:48Z | - |
dc.date.available | 2021-08-02T05:35:48Z | - |
dc.date.created | 2016-08-07 | - |
dc.date.issued | 2015-10 | - |
dc.identifier.issn | 2044-5385 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/42947 | - |
dc.description.abstract | Monosomal karyotype (MK) defined by either >= 2 autosomal monosomies or single monosomy with at least one additional structural chromosomal abnormality is associated with a dismal prognosis in patients with acute myeloid leukemia (AML). It was detected in 174 of 3041 AML patients in South Korean Registry. A total of 119 patients who had received induction therapy were finally analyzed to evaluate the predictive factors for a positive prognosis. On multivariate analysis, single monosomy, the absence of abn(17p), >= 10% of cells with normal metaphase and the achievement of a complete remission (CR) after induction therapy were significant factors for more favorable outcomes. Especially, single monosomy remained as a significantly independent prognostic factor for superior survival in both patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CR and who did not. Allo-HSCT in CR improved overall survival significantly only in patients with a single monosomy. Our results suggest that MK-AML may be biologically different according to the karyotypic subtype and that allo-HSCT in CR should be strongly recommended to patients with a single monosomy. For other patients, more prudent treatment strategies should be examined. Furthermore, the biological mechanism by which a single monosomy influences survival should be investigated. | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | COMPLEX ABERRANT KARYOTYPE | - |
dc.subject | PROGNOSTIC IMPACT | - |
dc.subject | POOR-PROGNOSIS | - |
dc.subject | MYELODYSPLASTIC SYNDROME | - |
dc.subject | POSTREMISSION THERAPY | - |
dc.subject | TP53 MUTATION | - |
dc.subject | DELETION | - |
dc.subject | ADULT | - |
dc.subject | SUBGROUP | - |
dc.title | Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, CW[Jung, C. W.] | - |
dc.contributor.affiliatedAuthor | Jang, JH[Jang, J. H.] | - |
dc.identifier.doi | 10.1038/bcj.2015.84 | - |
dc.identifier.scopusid | 2-s2.0-84989352624 | - |
dc.identifier.wosid | 000368920300008 | - |
dc.identifier.bibliographicCitation | BLOOD CANCER JOURNAL, v.5, no.10 | - |
dc.relation.isPartOf | BLOOD CANCER JOURNAL | - |
dc.citation.title | BLOOD CANCER JOURNAL | - |
dc.citation.volume | 5 | - |
dc.citation.number | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | COMPLEX ABERRANT KARYOTYPE | - |
dc.subject.keywordPlus | PROGNOSTIC IMPACT | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | MYELODYSPLASTIC SYNDROME | - |
dc.subject.keywordPlus | POSTREMISSION THERAPY | - |
dc.subject.keywordPlus | TP53 MUTATION | - |
dc.subject.keywordPlus | DELETION | - |
dc.subject.keywordPlus | ADULT | - |
dc.subject.keywordPlus | SUBGROUP | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.